Study of nemolizumab for moderate-to-severe eczema in Chinese patients
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new injected medication called nemolizumab for people with moderate-to-severe eczema (atopic dermatitis) that hasn't been controlled by creams or ointments. The goal is to see if it reduces symptoms like itching and skin inflammation better than a placebo (inactive shot).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and live in China.
- You have had eczema for at least 2 years, and it is moderate to severe (confirmed by a doctor).
- Your eczema covers at least 10% of your body surface area.
- You have tried prescription topical treatments (like steroid creams) and they did not control your eczema well enough.
- You agree to use topical corticosteroids (and possibly other topical medications) throughout the study as directed by the study doctor.
- If you are a woman who can become pregnant, you must use effective birth control or abstain from sex during the study and for 12 weeks after the last injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests if an oral tablet called ZL-82 can help people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to other treatments. It aims to find a new option for controlling this chronic skin condition.
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.